1
Home
Companies

4D Pharma

4D Pharma
Leadership team

Mr. Duncan Joseph Peyton (CEO & Exec. Director)

Dr. Alexander James Stevenson Ph.D. (Chief Scientific Officer & Exec. Director)

Mr. John Brendan Doyle (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Aberdeen, Aberdeen City, United Kingdom
Established
2014
Company Registration
SEC CIK number: 0001830162
Traded as
NASDAQ:LBPS
Social Media
URL
https://www.4dpharmaplc.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
History

4D Pharma plc was founded in 2014 after a spin-off from 4D Molecular Therapeutics, an American biotechnology company. It worked in collaboration with University of Nottingham and University of Edinburgh to identify and develop LB products. It became a public limited company in December 2015 and was admitted to AIM, a sub-market of the London Stock Exchange, in June 2016.

Mission
4D Pharma plc’s mission is to develop and deliver LB medicines to benefit patients and the medical community across multiple disease areas.
Vision
Our vision at 4D Pharma plc is to become a world-leading provider of LB medicines, with a pipeline of clinical development programmes and new LB product candidates.
Key Team

Ms. Fay Weston (Head of Investor Relations)

Mr. Adrian Murray (Gen. Counsel (Interim))

Mr. Glenn Dourado (Exec. VP of Corp. Devel.)

Ms. Lucy Christie (VP of HR)

Mr. Christophe Carite (Sr. VP of CMC & Process Devel.)

Ms. Imke Mulder (Exec. VP of Research)

Recognition and Awards
4D Pharma plc won the ‘Life Science/Health Care Company of the Year’ Award at the 9th Annual LSE & AIM Awards in 2017.
References

https://in.investing.com/equities/4d-pharma-plc

https://finance.yahoo.com/quote/DDDD.L/profile?p=DDDD.L

https://www.crunchbase.com/organization/4d-pharma-plc

https://www.4dpharmaplc.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

4D Pharma
Leadership team

Mr. Duncan Joseph Peyton (CEO & Exec. Director)

Dr. Alexander James Stevenson Ph.D. (Chief Scientific Officer & Exec. Director)

Mr. John Brendan Doyle (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Aberdeen, Aberdeen City, United Kingdom
Established
2014
Company Registration
SEC CIK number: 0001830162
Traded as
NASDAQ:LBPS
Social Media
URL
https://www.4dpharmaplc.com